Subject: FreeInvestBioReport Promo#: 1932529

From: "[email-masked]" <[email-masked]>
Date: Sat, 24 Nov 2001 10:39:43 -0500 (EST)

"This will symbolize to many people that we have the power to change human destiny. But the power is here and it's already being used."

William Haseltine, CEO of Human Genome Sciences

on the mapping of the human genome

Due to the recent ground breaking advances in DNA research, including the mapping of the human genome, biotechnology is positioned to become one of the most promising sectors on Wall Street.

Sifting through the science and understanding the FDA approval process can be a difficult task. InvestBio Report is building the bridge to allow individual investors access to easy-to-understand information and opportunities.

Our report also details the positive news and the latest research on the most common and life-affecting medical conditions.

Sign-up now to receive a free 6-month subscription of our InvestBio Report.

Please fill out the information below to receive a free issue of our InvestBio biotechnology research report.

Name:

»

Address:

»

»

City:

»

State/Zip:

»

Email:

»

Phone:

»

Our relationship with you is very important. In the event that you wish to
unsubscribe from future promotional e-mail or special offers from DBGI,
reply to this e-mail with a subject line of "unsubscribe". Once your request
is received, we will take prompt action to ensure you do not receive future
promotional e-mail from us.

Nothing on this Web site shall be considered a solicitation to buy or an
offer to sell a security to any person in any jurisdiction where such offer,
solicitation, purchase or sale would be unlawful under the securities laws
of such jurisdiction. Financial information and research is provided by
named third parties for general reference and education purposes only. DBGI
is not responsible for the quality or suitability of this information.
Trading in highly volatile sectors, such as Internet and biotechnology, may
expose investors to potentially rapid and substantial losses.

**